Evidence map›Paper›PMID 38711219›Full record

ArticleHealth expectations : an international journal of public participation in health care and health policy2024

'High hopes for treatment': Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases.

Christina Q Nguyen, Didu S T Kariyawasam, Tsz Shun Jason Ngai, James Nguyen, Kristine Alba-Concepcion, Sarah E Grattan, Elizabeth E Palmer, Kate Hetherington, Claire E Wakefield, Russell C Dale and 3 more

Abstract read
In one paragraph

Article in Health expectations : an international journal of public participation in health care and health policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Strategic consensus on the clinical translation of advanced therapies in paediatric rare neurological disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  3. Making Room for Every Voice: Reimagining Person-Centred Care in the Neurosciences.Health expectations : an international journal of public participation in health care and health policy · 2025
    Article
  4. 'High hopes for treatment': Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases.Health expectations : an international journal of public participation in health care and health policy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christina Q NguyenDiscipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.ORCID 0000-0003-2952-2665
Didu S T KariyawasamDiscipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.ORCID 0000-0002-4176-4010
Tsz Shun Jason NgaiDiscipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.
James NguyenDiscipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.
Kristine Alba-ConcepcionDiscipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.ORCID 0000-0002-0095-8433
Sarah E GrattanDiscipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.ORCID 0000-0003-4675-8944
Elizabeth E PalmerDiscipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.ORCID 0000-0003-1844-215X
Kate HetheringtonDiscipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.ORCID 0000-0002-5457-5462
Claire E WakefieldDiscipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.ORCID 0000-0001-7704-7067
Russell C DaleDepartment of Neurology, Sydney Children's Hospital Network, Sydney, New South Wales, Australia.ORCID 0000-0002-2495-1826
Sue WoolfendenChildren's Hospital Westmead Clinical School, Faculty of Medicine and Health, Sydney Medical School, University of Sydney, Sydney, Australia.ORCID 0000-0002-6954-5071
Shekeeb MohammadDepartment of Neurology, Sydney Children's Hospital Network, Sydney, New South Wales, Australia.ORCID 0000-0003-1219-4781
Michelle A FarrarDiscipline of Paediatrics and Child Health, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.ORCID 0000-0002-4472-0902

Funding

Cerebral Palsy Alliance Research Foundation PRG09821Medical Research Council 1194940National Health and Medical Research Council 1194940
6 · The paper itself

Abstract

introductionAdvanced therapies offer unprecedented opportunities for treating rare neurological disorders (RNDs) in children. However, health literacy, perceptions and understanding of novel therapies need elucidation across the RND community. This study explored healthcare professionals' and carers' perspectives of advanced therapies in childhood-onset RNDs.

methodsIn this mixed-methodology cross-sectional study, 20 healthcare professionals (clinicians, genetic counsellors and scientists) and 20 carers completed qualitative semistructured interviews and custom-designed surveys. Carers undertook validated psychosocial questionnaires. Thematic and quantitative data analysis followed.

resultsParticipants described high positive interest in advanced therapies, but low knowledge of, and access to, reliable information. The substantial 'therapeutic gap' and 'therapeutic odyssey' common to RNDs were recognised in five key themes: (i) unmet need and urgency for access; (ii) seeking information; (iii) access, equity and sustainability; (iv) a multidisciplinary and integrated approach to care and support and (v) difficult decision-making. Participants were motivated to intensify RND clinical trial activity and access to advanced therapies; however, concerns around informed consent, first-in-human trials and clinical trial procedures were evident. There was high-risk tolerance despite substantial uncertainties and knowledge gaps. RNDs with high mortality, increased functional burdens and no alternative therapies were consistently prioritised for the development of advanced therapies. However, little consensus existed on prioritisation to treatment access.

conclusionsThis study highlights the need to increase clinician and health system readiness for the clinical translation of advanced therapeutics for RNDs. Co-development and use of educational and psychosocial resources to support clinical decision-making, set therapeutic expectations and promotion of equitable, effective and safe delivery of advanced therapies are essential. PATIENT OR PUBLIC CONTRIBUTION: Participant insights into the psychosocial burden and information need to enhance the delivery of care in this formative study are informing ongoing partnerships with families, including co-production and dissemination of psychoeducational resources featuring their voices hosted on the Sydney Children's Hospitals Network website SCHN Brain-Aid Resources.

Indexed as

Nervous System DiseasesRare DiseasesAdultAustraliaCaregiversCross-Sectional StudiesFemaleHealth PersonnelHumansInterviews as TopicMaleMiddle AgedQualitative ResearchStakeholder ParticipationSurveys and QuestionnairesTranslational Research, Biomedicaladvanced therapeuticsclinical decision‐makingpaediatric neurologypatient advocacyprecision medicinerare diseases

Identifiers

PMID38711219
PMCPMC11074375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.